



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	104.55
Trade Time:	4:00 PM ET Jan 23, 2018
Change:	1.64 (1.594%)
Day Range	103.00 - 106.28
52-Week Range	94.55 - 147.17
Volume	10,546,653

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

Jan 22, 2018

[Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy](#)

Jan 19, 2018

[Investigational Data Presented at ASCO GI Evaluate ABRAXANE® Regimen for Patients with Locally Advanced Pancreatic Cancer](#)

Jan 8, 2018

[Celgene Corporation Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance](#)

Jan 7, 2018

[Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies](#)

Jan 3, 2018

[Celgene Corporation to Announce Fourth Quarter and Full-Year 2017 Results on January 25, 2018](#)

### Upcoming Events [\[ View all \]](#)

Jan 25, 2018 9:00 AM ET

[Celgene Corporation Q4 2017 Earnings Conference Call](#)

### Events [\[ View all \]](#)

### Financials [\[ View all \]](#)

Feb 10, 2017

[Annual Report \(10-K\)](#)

Apr 27, 2017

[Proxy Statement \(DEF 14A\)](#)

Oct 26, 2017

[Quarterly Report \(10-Q\)](#)

Jul 27, 2017

[Quarterly Report \(10-Q\)](#)

Apr 27, 2017

[Quarterly Report \(10-Q\)](#)